Affini-T Therapeutics


affini-t health logo

Vision

Powering T cells to cure solid tumors.

Approach

Affini-T is unlocking the power of T cells and targeting core oncogenic drivers to develop potentially curative therapies for solid tumor cancers. Our differentiated cell therapy platform harnesses state-of-the-art engineering, and synthetic biology capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T-cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last.

Affini-T Therapeutics is addressing

CEO:

Jak Knowles, MD (Co-Founder and CEO)

Founders:

Phil Greenberg, M.D. (Scientific Co-founder)

Aude Chapuis, M.D. (Scientific Co-founder)

Tom Schmitt, Ph.D. (Scientific Co-founder)

Arjun Goyal M.D., M.Phil. (Co-founder)

Vida Ventures (Co-founder)

First investment:

March 2022